Search Results - "Ds Lightfoot, Michelle"

Ensuring equal access: Language as exclusion criteria among clinical trials in gynecologic oncology by Lee, Sarah S., Dinicu, Andreea, Arthurs, Likolani, Seda, Danielle, Pothuri, Bhavana, Lightfoot, Michelle DS

“…e18587 Background: Enrolling a diverse patient population into clinical trials may help mitigate disparities and ensure generalizability of results. We aimed…”
Get full text

Demographic reporting and language exclusion in gynecologic oncology clinical trials by Lee, Sarah S., Dinicu, Andreea, Arthurs, Likolani, Shileds, Danielle, Pothuri, Bhavana, Ds Lightfoot, Michelle

“…Participation in clinical trials may help mitigate disparate cancer outcomes. Ensuring equitable access to clinical trials is thus a major priority for…”
Get full text

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date by Montemorano, Lauren, Lightfoot, Michelle Ds, Bixel, Kristin

“…PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for…”
Get full text

Assessment of the feasibility of same-day discharge following minimally invasive hysterectomy in the elderly population by Haight, Paulina J, Piver, Rachael N, Barrington, David A, Baek, Jae, Graves, Stephen M, Ardizzone, Melissa, Akinduro, Jenifer A, Busho, Audrey C, Fadoju, Deborah, Pandit, Radhika, Stephens, Raeshawn, Strowder, Lauren M, Tadepalli, Shreekari, VanNoy, Brianna, Sriram, Bhargavi, McLaughlin, Eric M, DS Lightfoot, Michelle, Chambers, Laura M, Bixel, Kristin L, Cohn, David E, Cosgrove, Casey M, O'Malley, David, Salani, Ritu, Backes, Floor J, I Nagel, Christa

“…•Advanced age alone should not serve as contraindication to same-day discharge following minimally invasive hysterectomy.•Elderly patients who undergo same-day…”
Get full text

Abstract LB156: Identified the ISG15 mediated extracellular vesicles drives ovarian cancer progression and metastasis: extracellular vesicular ISG15 is a potential biomarker and therapeutic target by Dorayappan, Kalpana Deepa Priya, Wagner, Vincent, Park, Dongju, Newcomer, Meghan M., Lightfoot, Michelle DS, Kalaiyarasan, Deepika, Sakaue, Takahiko, Khadraoui, Wafa, Cosgrove, Casey, Maxwell, Larry J., Wang, Qi-En Wang, O’Malley, David, Pollock, Raphael E., Cohn, David E., Karuppaiyah, Selvendiran

“…Abstract Background & Objective: High-grade serous ovarian cancer (HGSOC) accounts for over 80% of all epithelial ovarian cancer (OC) diagnoses, and the…”
Get full text